<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="nephrology" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JOHS</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
      <journal-title-group>
        <journal-title>Journal of HealthCare Sciences</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">392</article-id>
      <article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2025.50111</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Nephrology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evaluating the Efficacy of SGLT2 Inhibitors in Preventing Diabetic Kidney Disease&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Alharbi</surname>
            <given-names>Samar Abed</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alqahtani</surname>
            <given-names>Abdullah Mushabab</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alnasser</surname>
            <given-names>Shahad Nasser</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alfuhaydi</surname>
            <given-names>Ghadeer Lafi</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alrowithi</surname>
            <given-names>Raghad Adel</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Asiri</surname>
            <given-names>Fawzia Ayedh</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almutairi</surname>
            <given-names>Ahmed Ammar</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>25</day>
        <month>01</month>
        <year>2025</year>
      </pub-date>
      <volume>5</volume>
      <issue>1</issue>
      <fpage>85</fpage>
      <lpage>92</lpage>
      <permissions>
        <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Diabetic kidney disease (DKD) remains one of the leading causes of morbidity and mortality in diabetic patients, and there are very few therapeutic options that can halt its progression. SGLT2 inhibitors were developed to lower glucose, but they have also demonstrated highly significant renal and cardiovascular benefits independent of their glucose-lowering effects. This article summarizes, based on evidence from clinical trials and meta-analysis, the efficacy of SGLT2 inhibitors in preventing diabetic kidney disease. EMPA-REG OUTCOME, CANVAS, and DAPA-CKD trials have suggested that SGLT2 inhibitors drugs have renal benefit effects. This review also discusses safety profiles, emphasizing that a proper balance exists between efficacy and adverse effects, with a low but manageable risk for genitourinary infections. The current guidelines advocate the supplementation of SGLT2 inhibitors to usual care in patients with DKD, especially those who are at high risk for cardiovascular or renal outcomes. In summary, SGLT2 inhibitors represent a paradigm shift in the management of DKD, supported by robust evidence from trials that have clearly demonstrated their benefits for renal outcomes. The advantages may be related to several processes, such as decreased intraglomerular pressure, enhanced hemodynamic stability, and decreased renal inflammation. Crucially, renal advantages are also present in both diabetic and nondiabetic patients, underlining their wide range of applications in nephroprotection. Future studies should be directed at long-term and large-scale clinical trials assessing the efficacy and mechanisms of SGLT2 inhibitors for preventing DKD. Per the current guidelines, patients with DKD at high risk for renal consequences should be administered SGLT2 inhibitors in addition to their regular therapy.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>SGLT2 inhibitors</kwd>
        <kwd> Diabetic kidney disease</kwd>
        <kwd> Renal outcomes</kwd>
        <kwd> Diabetes management</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>